# Using Serum Advanced Glycation End Products-Peptides to Improve the Efficacy of World Health Organization Fasting Plasma Glucose Criterion in Screening for Diabetes in High-Risk Chinese Subjects

**Authors:** Zilin Sun, Jiajia He, Shanhu Qiu, Chenghao Lei, Yi Zhou, Zuolin Xie, Lin Zhang, Yanping Wang, Hui Jin

PMC · DOI: 10.1371/journal.pone.0137756 · PLoS ONE · 2015-09-14

## TL;DR

This study shows that combining fasting plasma glucose with a new blood marker improves diabetes screening in high-risk Chinese individuals.

## Contribution

Introduces serum advanced glycation end products-peptides as a novel biomarker to enhance diabetes screening accuracy.

## Key findings

- The FPG-sAGEP model had the largest area under the ROC curve for diabetes screening in high-risk subjects.
- The optimal FPG-sAGEP model achieved 91.2% sensitivity in detecting diabetes, outperforming existing methods.
- Only 41.7% of diabetes cases were identified using the WHO FPG criterion alone in this population.

## Abstract

The efficacy of using fasting plasma glucose (FPG) alone as a preferred screening test for diabetes has been questioned. This study was aimed to evaluate whether the use of serum advanced glycation end products-peptides (sAGEP) would help to improve the efficacy of FPG in diabetes screening among high-risk Chinese subjects with FPG <7.0 mmol/L. FPG, 2-h plasma glucose (2h-PG), serum glycated haemoglobin A1c (HbA1c), and sAGEP were measured in 857 Chinese subjects with risk factors for diabetes. The areas under receiver operating characteristic (ROC) curves generated by logistic regression models were assessed and compared to find the best model for diabetes screening in subjects with FPG <7.0 mmol/L. The optimal critical line was determined by maximizing the sum of sensitivity and specificity. Among the enrolled subjects, 730 of them had FPG <7.0 mmol/L, and only 41.7% new diabetes cases were identified using the 1999 World Health Organization FPG criterion (FPG ≥7.0 mmol/L). The area under ROC curves generated by the model on FPG-sAGEP was the largest compared with that on FPG-HbA1c, sAGEP, HbA1c or FPG in subjects with FPG <7.0 mmol/L. By maximizing the sum of sensitivity and specificity, the optimal critical line was determined as 0.69×FPG + 0.14×sAGEP = 7.03, giving a critical sensitivity of 91.2% in detecting 2h-PG ≥11.1 mmol/L, which was significantly higher than that of FPG-HbA1c or HbA1c. The model on FPG-sAGEP improves the efficacy of using FPG alone in detecting diabetes among high-risk Chinese subjects with FPG <7.0 mmol/L, and is worth being promoted for future diabetes screening.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Diseases:** IGR (MESH:C565631), insulin resistance (MESH:D007333), FPG (MESH:D007003), diabetic retinopathy (MESH:D003930), cancer (MESH:D009369), psychiatric disturbance (MESH:D001523), Diabetes (MESH:D003920), obese (MESH:D009765), heart-cerebro-vascular disease (MESH:D014652), chronic kidney disease (MESH:D051436), hyperglycemia (MESH:D006943), hyperlipidemia (MESH:D006949), overweight (MESH:D050177), polycystic ovary syndrome (MESH:D011085), kidney disease (MESH:D007674), impaired glucose (MESH:D044882), IGT (MESH:D018149), gestational diabetes (MESH:D016640), cardiovascular disease (MESH:D002318), diabetic nephropathy (MESH:D003928), AGE (MESH:D003643), hypertension (MESH:D006973), acute kidney injury (MESH:D058186)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A1C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4569373/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4569373/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC4569373/full.md

---
Source: https://tomesphere.com/paper/PMC4569373